# ![@zohmbastic Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::2273512572.png) @zohmbastic zohm

No specific company named "zohm" appears in the provided tweets. However, various companies are trending with updates on earnings, analyst upgrades and downgrades, and new partnerships. Some companies like $MARa, $FIVE, and $RLX reported strong quarterly earnings.

### Engagements: [------] [#](/creator/twitter::2273512572/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2273512572/c:line/m:interactions.svg)

- [--] Week [-------] +27%
- [--] Month [---------] +6.90%
- [--] Months [----------] +145%
- [--] Year [----------] +177%

### Mentions: [---] [#](/creator/twitter::2273512572/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2273512572/c:line/m:posts_active.svg)

- [--] Week [---] -3.70%
- [--] Month [-----] +27%
- [--] Months [-----] +133%
- [--] Year [-----] +149%

### Followers: [------] [#](/creator/twitter::2273512572/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2273512572/c:line/m:followers.svg)

- [--] Week [------] +0.35%
- [--] Month [------] +3.30%
- [--] Months [------] +24%
- [--] Year [------] +53%

### CreatorRank: [-------] [#](/creator/twitter::2273512572/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2273512572/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  68.1% [finance](/list/finance)  16.77% [cryptocurrencies](/list/cryptocurrencies)  9.2% [exchanges](/list/exchanges)  #4878 [financial services](/list/financial-services)  3.26% [technology brands](/list/technology-brands)  3.26% [countries](/list/countries)  2.23% [fashion brands](/list/fashion-brands)  0.89% [vc firms](/list/vc-firms)  0.3% [currencies](/list/currencies)  0.3%

**Social topic influence**
[target](/topic/target) #2253, [strong](/topic/strong) 4.75%, [nasdaq](/topic/nasdaq) #536, [company](/topic/company) #2024, [rating](/topic/rating) #1009, [$ua](/topic/$ua) #14, [in the](/topic/in-the) 2.52%, [morgan stanley](/topic/morgan-stanley) 2.37%, [$fsly](/topic/$fsly) #19, [ai](/topic/ai) 2.23%

**Top accounts mentioned or mentioned by**
[@doepke_michel](/creator/undefined) [@pnani456](/creator/undefined) [@byebyegoodguy](/creator/undefined) [@brenbto](/creator/undefined) [@maximusholla](/creator/undefined) [@sunrgu](/creator/undefined) [@jpvantage25](/creator/undefined) [@trade_velocity](/creator/undefined) [@rdglinvestors](/creator/undefined) [@monaco_biotech](/creator/undefined) [@hellojintao](/creator/undefined) [@alexgiovannetti](/creator/undefined) [@mwm76](/creator/undefined) [@bigchodu](/creator/undefined) [@traderbasha](/creator/undefined) [@erictheumpire](/creator/undefined)

**Top assets mentioned**
[Under Armour Inc Class C (UA)](/topic/$ua) [Morgan Stanley (MS)](/topic/morgan-stanley) [Fastly, Inc. (FSLY)](/topic/$fsly) [Under Armour Inc Class A (UAA)](/topic/$uaa) [Goldman Sachs (GS)](/topic/goldman-sachs) [AT&T Inc. (T)](/topic/$t) [BioAge Labs, Inc. (BIOA)](/topic/$bioa) [Erasca, Inc.  (ERAS)](/topic/$eras) [Arteris, Inc. (AIP)](/topic/$aip) [Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)](/topic/$teva) [Olema Pharmaceuticals, Inc. (OLMA)](/topic/$olma) [Alumis Inc. (ALMS)](/topic/$alms) [Beta Finance (BETA)](/topic/$beta) [Cosmos (ATOM)](/topic/$atom) [HealthSci.AI (HSAI)](/topic/$hsai) [Kenvue Inc. (KVUE)](/topic/$kvue) [Comcast Corporation (CMCSA)](/topic/$cmcsa) [Verizon Communications Inc. (VZ)](/topic/$vz) [TeraWulf Inc. (WULF)](/topic/$wulf) [ACV Auctions Inc. (ACVA)](/topic/$acva) [Terns Pharmaceuticals, Inc. (TERN)](/topic/$tern) [Devon Energy Corp (DVN)](/topic/$dvn) [Viavi Solutions Inc. Common Stock (VIAV)](/topic/$viav) [Corsair Gaming, Inc. (CRSR)](/topic/$crsr) [Unicycive Therapeutics, Inc. (UNCY)](/topic/$uncy) [GitLab Inc. (GTLB)](/topic/$gtlb) [AB (prev. Newton) (AB)](/topic/$ab) [Carnival Corp (CCL)](/topic/$ccl) [ALX Oncology Holdings Inc (ALXO)](/topic/$alxo) [Landwolf (WOLF)](/topic/$wolf) [Core Scientific, Inc. Common Stock (CORZ)](/topic/$corz) [Lumentum Holdings Inc. Common Stock (LITE)](/topic/$lite) [Immunome, Inc. (IMNM)](/topic/$imnm) [Taysha Gene Therapies, Inc. (TSHA)](/topic/$tsha) [2131KOBUSHIDE (21)](/topic/$21) [Ramaco Resources, Inc. Common Stock (METC)](/topic/$metc) [Brookdale Senior Living, Inc. (BKD)](/topic/$bkd) [Applied Optoelectronics, Inc. (AAOI)](/topic/$aaoi) [nLIGHT, Inc. Common Stock (LASR)](/topic/$lasr) [Evommune, Inc. (EVMN)](/topic/$evmn) [Super Micro Computer, Inc. Common Stock (SMCI)](/topic/$smci) [Immix Biopharma, Inc.  (IMMX)](/topic/$immx) [Fermi Inc. (FRMI)](/topic/$frmi) [Warby Parker, Inc. (WRBY)](/topic/$wrby) [Tyra Biosciences, Inc. (TYRA)](/topic/$tyra) [Anteris Technologies Global Corp. (AVR)](/topic/$avr) [Venture Global, Inc (VG)](/topic/$vg) [Intuitive Machines, Inc. (LUNR)](/topic/$lunr) [Coterra Energy Inc (CTRA)](/topic/$ctra) [Lumen Technologies Inc (LUMN)](/topic/$lumn) [Context Therapeutics Inc. (CNTX)](/topic/$cntx) [Eli Lilly and Company (LLY)](/topic/$lly) [GoodRx Holdings, Inc. (GDRX)](/topic/$gdrx) [Pfizer, Inc. (PFE)](/topic/$pfe) [Envista Holdings Corporation Common stock, $0.01 par value per share (NVST)](/topic/$nvst) [Canton (CC)](/topic/$cc) [Arista Networks Inc (ANET)](/topic/$anet) [Abivax SA (ABVX)](/topic/$abvx)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$SMCI intra highs $SMCI https://t.co/8Pn1r48bEL $SMCI https://t.co/8Pn1r48bEL"  
[X Link](https://x.com/zohmbastic/status/2019871921001873718)  2026-02-06T20:32Z 10.1K followers, [----] engagements


"$CTMX Barclays raised the firm's price target on CytomX Therapeutics to $10 from $8 and keeps an Overweight rating on the shares as part of a Q4 earnings preview for the biotechnology group. $CTMX continuation https://t.co/TIu8ho8kk9 $CTMX continuation https://t.co/TIu8ho8kk9"  
[X Link](https://x.com/zohmbastic/status/2022332901917164014)  2026-02-13T15:31Z 10.1K followers, [----] engagements


"$ATOM [--] / [----] potential from here $ATOM maybe mid 3.8s / [--] big zone $ATOM maybe mid 3.8s / [--] big zone"  
[X Link](https://x.com/zohmbastic/status/2022405363174428957)  2026-02-13T20:19Z 10.1K followers, [----] engagements


"$CPNG [--] $CPNG if 17.5ish cracks may had to [--] $CPNG if 17.5ish cracks may had to 15"  
[X Link](https://x.com/zohmbastic/status/2019498569741258993)  2026-02-05T19:49Z 10.1K followers, [----] engagements


"$MMM teased today"  
[X Link](https://x.com/zohmbastic/status/2022012174546386999)  2026-02-12T18:17Z 10.1K followers, [---] engagements


"$NKTR some 70c hit then some 60p sellers $NKTR [--] $NKTR 70"  
[X Link](https://x.com/zohmbastic/status/2022366289205813414)  2026-02-13T17:44Z 10.1K followers, [----] engagements


"$WULF $WULF pcr .144 so far largest $vol and con vol Feb 16c highest OI March 20c $WULF pcr .144 so far largest $vol and con vol Feb 16c highest OI March 20c"  
[X Link](https://x.com/zohmbastic/status/2021966481320554884)  2026-02-12T15:15Z 10.1K followers, [----] engagements


"$FSLY trimmed couple more [-----] $FSLY [--] holla $FSLY [--] holla"  
[X Link](https://x.com/zohmbastic/status/2022342972369773045)  2026-02-13T16:11Z 10.1K followers, [----] engagements


"$CLYM [--] break today Piper Sandler $23 pt Piper Sandler initiated coverage of Climb Bio with an Overweight rating and $23 price target. The company is developing budoprutug across three indications and CLYM116 in Berger's disease the analyst tells investors in a research note. Piper says Climb Bio has "multiple shots on goal to unlock significant value" heading into a catalyst-rich [----]. $CLYM https://t.co/tA7WEIF67w $CLYM https://t.co/tA7WEIF67w"  
[X Link](https://x.com/zohmbastic/status/2022372262457057571)  2026-02-13T18:08Z 10.1K followers, [----] engagements


"$LITE June 760c sweep $LITE nearing [---] https://t.co/PjE8FJJfNE $LITE nearing [---] https://t.co/PjE8FJJfNE"  
[X Link](https://x.com/zohmbastic/status/2022413386810888547)  2026-02-13T20:51Z 10.1K followers, [----] engagements


"$NKTR not bad $NKTR right on time good offering Nektar Therapeutics (Nasdaq: NKTR) a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy today announced that it has commenced an underwritten public $NKTR right on time good offering Nektar Therapeutics (Nasdaq: NKTR) a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy today announced that it has commenced an underwritten public"  
[X Link](https://x.com/zohmbastic/status/2021618518773371039)  2026-02-11T16:13Z 10.1K followers, [----] engagements


"$IMNM H.C. Wainwright initiated coverage of Immunome with a Buy rating and $40 price target. The company is building a portfolio of "best-in-class pipeline-in-a-product oncology assets with meaningful differentiation across both validated and underpenetrated solid tumor and hematologic indications" the analyst tells investors in a research note. H.C. Wainwright sees Immunome's portfolio as a "coordinated set of value drivers." $IMNM Evercore ISI raised the firm's price target on Immunome to $40 from $18 and keeps an Outperform rating on the shares. The "overwhelmingly positive" results from"  
[X Link](https://x.com/zohmbastic/status/2021926406175723782)  2026-02-12T12:36Z 10.1K followers, [----] engagements


"$NKTR $NKTR not bad https://t.co/2XDr3ICXpB $NKTR not bad https://t.co/2XDr3ICXpB"  
[X Link](https://x.com/zohmbastic/status/2021970564165124255)  2026-02-12T15:32Z 10.1K followers, [----] engagements


"$IRD PIPE for convertible preferred stock Opus Genetics Inc. (Nasdaq: IRD) (Opus Genetics or the Company) a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) today announced that it has entered into a securities purchase agreement for a private placement (the private placement) of [-------] shares of its Series B Non-Voting Convertible Preferred Stock at a price of $3.39 per share. Subject to Opus Genetics stockholder approval of an increase to the authorized shares of common stock"  
[X Link](https://x.com/zohmbastic/status/2022290497159495859)  2026-02-13T12:43Z 10.1K followers, [----] engagements


"$FSLY [--] holla $FSLY https://t.co/pLHfiZK2Pf $FSLY https://t.co/pLHfiZK2Pf"  
[X Link](https://x.com/zohmbastic/status/2022341946468094224)  2026-02-13T16:07Z 10.1K followers, [----] engagements


"$FSLY [--] holla $FSLY wen [--] $FSLY wen 19"  
[X Link](https://x.com/zohmbastic/status/2022398770886132189)  2026-02-13T19:53Z 10.1K followers, [----] engagements


"$UNH decent eod $UNH https://t.co/kRKfM9aSf7 $UNH https://t.co/kRKfM9aSf7"  
[X Link](https://x.com/zohmbastic/status/2022414457172038027)  2026-02-13T20:55Z 10.1K followers, [----] engagements


"$IMRX Immuneering Corporation (Nasdaq: IMRX) a clinical-stage oncology company focused on keeping cancer patients alive today announced a clinical supply agreement with Eli Lilly and Company (NYSE:LLY) for its second-generation KRAS G12C inhibitor olomorasib (LY3537982). The supply agreement supports the evaluation of Immuneerings lead product candidate atebimetinib (IMM-1-104) a novel dual MEK inhibitor in combination with olomorasib in a planned Phase [--] clinical trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on"  
[X Link](https://x.com/zohmbastic/status/1959949093536481484)  2025-08-25T12:00Z 10.1K followers, [----] engagements


"$NKTX 2H catalyst Ra #1 holder cash 3.19/sh fwiw $NKTX [---] key https://t.co/UhpjNx8l34 $NKTX [---] key https://t.co/UhpjNx8l34"  
[X Link](https://x.com/zohmbastic/status/1978522864652374179)  2025-10-15T18:06Z 10.1K followers, [----] engagements


"$TSHA looks like more upside can come RJ pt [--] Raymond James initiated coverage of Taysha Gene Therapies with a Strong Buy rating and $13 price target. Based on "strong results" from Part A of the Phase 1/2 REVEAL trial and "constructive" feedback from FDA the firm views Taysha as well-positioned for success in its pivotal trial for patients with Rett syndrome the analyst tells investors. There are currently no approved therapies addressing the root genetic cause of Rett syndrome which the firm sees giving Taysha "a clear path to success" the analyst added. $TSHA Previously disclosed 100%"  
[X Link](https://x.com/zohmbastic/status/1980368349453234393)  2025-10-20T20:19Z 10.1K followers, [----] engagements


"$MLCO ww especially after regular session open Casino sector doing well has presence in Asia quite positive looking ER # across Macau Cyprus Philliphines region. Melco Resorts and Enter Q3 Adj. EPS $0.21 Beats $0.12 Estimate Sales $1.309B Beat $1.282B Estimate"  
[X Link](https://x.com/zohmbastic/status/1986429486317875642)  2025-11-06T13:44Z 10.1K followers, [----] engagements


"$ACVA https://www.sec.gov/Archives/edgar/data/1252022/000119312525278383/xslF345X05/ownership.xml https://www.sec.gov/Archives/edgar/data/1252022/000119312525278383/xslF345X05/ownership.xml"  
[X Link](https://x.com/zohmbastic/status/1989034000787051007)  2025-11-13T18:13Z 10.1K followers, [----] engagements


"$acva https://www.sec.gov/Archives/edgar/data/1637873/000185160525000003/0001851605-25-000003-index.htm $ACVA https://t.co/IiAAqISCDu https://t.co/FPB4S17mTW https://www.sec.gov/Archives/edgar/data/1637873/000185160525000003/0001851605-25-000003-index.htm $ACVA https://t.co/IiAAqISCDu https://t.co/FPB4S17mTW"  
[X Link](https://x.com/zohmbastic/status/1989465951151296776)  2025-11-14T22:50Z 10.1K followers, [----] engagements


"$ACVA more https://www.sec.gov/Archives/edgar/data/1637873/000180880625000003/xslF345X05/wk-form4_1763500606.xml $acva https://t.co/3vDMjoK0Ja https://www.sec.gov/Archives/edgar/data/1637873/000180880625000003/xslF345X05/wk-form4_1763500606.xml $acva https://t.co/3vDMjoK0Ja"  
[X Link](https://x.com/zohmbastic/status/1990892389351694622)  2025-11-18T21:18Z 10.1K followers, [----] engagements


"$SG $SG hit 6.6s today https://t.co/thizNVnCeB $SG hit 6.6s today https://t.co/thizNVnCeB"  
[X Link](https://x.com/zohmbastic/status/1991966164516565355)  2025-11-21T20:25Z 10.1K followers, [----] engagements


"$CGEM that 15c up quite a bit $CGEM https://t.co/JQmrVZwzlv $CGEM https://t.co/JQmrVZwzlv"  
[X Link](https://x.com/zohmbastic/status/1993039024744022435)  2025-11-24T19:28Z 10.1K followers, [----] engagements


"$ACVA [--] $ACVA more https://t.co/fpJZmkUsDu $ACVA more https://t.co/fpJZmkUsDu"  
[X Link](https://x.com/zohmbastic/status/1993053657622102222)  2025-11-24T20:26Z 10.1K followers, [----] engagements


"$ACVA locked a few 7.4s $ACVA [--] https://t.co/rY0Dx34RPe $ACVA [--] https://t.co/rY0Dx34RPe"  
[X Link](https://x.com/zohmbastic/status/1993334501951611361)  2025-11-25T15:02Z 10.1K followers, [----] engagements


"$GAP 25c decent so far too $GAP https://t.co/tkEyflTUjn $GAP https://t.co/tkEyflTUjn"  
[X Link](https://x.com/zohmbastic/status/1993384831548522729)  2025-11-25T18:22Z 10K followers, [----] engagements


"$ACVA decent vol pop $ACVA locked a few 7.4s https://t.co/5c8Ugz4OaE $ACVA locked a few 7.4s https://t.co/5c8Ugz4OaE"  
[X Link](https://x.com/zohmbastic/status/1993783555701510625)  2025-11-26T20:46Z 10.1K followers, [----] engagements


"$MLCO $MLCO ww especially after regular session open Casino sector doing well has presence in Asia quite positive looking ER # across Macau Cyprus Philliphines region. Melco Resorts and Enter Q3 Adj. EPS $0.21 Beats $0.12 Estimate Sales $1.309B Beat $1.282B Estimate $MLCO ww especially after regular session open Casino sector doing well has presence in Asia quite positive looking ER # across Macau Cyprus Philliphines region. Melco Resorts and Enter Q3 Adj. EPS $0.21 Beats $0.12 Estimate Sales $1.309B Beat $1.282B Estimate"  
[X Link](https://x.com/zohmbastic/status/1995504572111233259)  2025-12-01T14:45Z 10.1K followers, [----] engagements


"$ACVA nearing [--] $ACVA decent vol pop $ACVA decent vol pop"  
[X Link](https://x.com/zohmbastic/status/1995507461575614504)  2025-12-01T14:57Z 10.1K followers, [----] engagements


"$AIP weekly $AIP https://t.co/bTWlyaHeBu $AIP https://t.co/bTWlyaHeBu"  
[X Link](https://x.com/zohmbastic/status/1995872998126223515)  2025-12-02T15:09Z 10.1K followers, [----] engagements


"$AIP $AIP weekly https://t.co/gxYk4kkFus $AIP weekly https://t.co/gxYk4kkFus"  
[X Link](https://x.com/zohmbastic/status/1996289087645589626)  2025-12-03T18:43Z 10.1K followers, [----] engagements


"$BLND $BLND vs 3-3.05 zone https://t.co/4kRtBl0413 $BLND vs 3-3.05 zone https://t.co/4kRtBl0413"  
[X Link](https://x.com/zohmbastic/status/1996593308466868482)  2025-12-04T14:51Z 10.1K followers, [----] engagements


"$TSHA back to [--] $TSHA daily bnce https://t.co/pUxpRopCzS $TSHA daily bnce https://t.co/pUxpRopCzS"  
[X Link](https://x.com/zohmbastic/status/1996606006613119356)  2025-12-04T15:42Z 10.1K followers, [----] engagements


"$AIP $AIP https://t.co/I1DrZX4jTD $AIP https://t.co/I1DrZX4jTD"  
[X Link](https://x.com/zohmbastic/status/1996626848638554197)  2025-12-04T17:05Z 10.1K followers, [----] engagements


"$BMEA BMEA Biomea Fusion Reports Durable Glycemic And C-Peptide Improvements [--] Months After Last Dose In COVALENT-111 With Icovamenib $BMEA https://t.co/AJjw0UObjO $BMEA https://t.co/AJjw0UObjO"  
[X Link](https://x.com/zohmbastic/status/1996934978723012619)  2025-12-05T13:29Z 10.1K followers, [----] engagements


"$AIP 17.2ish key being tested $AIP https://t.co/eOYp4n9jIC $AIP https://t.co/eOYp4n9jIC"  
[X Link](https://x.com/zohmbastic/status/1996982084506698192)  2025-12-05T16:36Z 10.1K followers, [----] engagements


"$CNX Jan 38c large sweep"  
[X Link](https://x.com/zohmbastic/status/1996985685954171293)  2025-12-05T16:51Z 10.1K followers, [---] engagements


"$AIP $AIP 17.2ish key being tested $AIP 17.2ish key being tested"  
[X Link](https://x.com/zohmbastic/status/1997002713410802067)  2025-12-05T17:58Z 10.1K followers, [----] engagements


"$SG decent come back one of sqz candidates $SG https://t.co/AzwIKkDENB $SG https://t.co/AzwIKkDENB"  
[X Link](https://x.com/zohmbastic/status/1998454286200504462)  2025-12-09T18:06Z 10.1K followers, [----] engagements


"$BLND $BLND vs 3-3.05 zone https://t.co/4kRtBl0413 $BLND vs 3-3.05 zone https://t.co/4kRtBl0413"  
[X Link](https://x.com/zohmbastic/status/1998475272589553905)  2025-12-09T19:30Z 10.1K followers, [----] engagements


"$ABSI https://www.sec.gov/Archives/edgar/data/1672688/000167268825000096/xslF345X05/wk-form4_1765314257.xml https://www.sec.gov/Archives/edgar/data/1672688/000167268825000096/xslF345X05/wk-form4_1765314257.xml"  
[X Link](https://x.com/zohmbastic/status/1998499506741194957)  2025-12-09T21:06Z 10.1K followers, [----] engagements


"$CMPS Oppenheimer upgraded Compass Pathways to Outperform from Perform with a $15 price target"  
[X Link](https://x.com/zohmbastic/status/1998500619796054383)  2025-12-09T21:10Z 10.1K followers, [----] engagements


"$IMMX Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Financing includes leading U.S. biotechnology institutional investors and mutual funds Morgan Stanley was a book-running manager $IMMX near [--] $IMMX near 7"  
[X Link](https://x.com/zohmbastic/status/1998549245750817054)  2025-12-10T00:24Z 10.1K followers, [----] engagements


"$IMMX $3 run ever since daily break $IMMX https://t.co/w4RggMrHYA $IMMX https://t.co/w4RggMrHYA"  
[X Link](https://x.com/zohmbastic/status/1998776870268018705)  2025-12-10T15:28Z 10.1K followers, [----] engagements


"$GEMI 14s $GEMI pcr .164 https://t.co/lpg5vHeXQD $GEMI pcr .164 https://t.co/lpg5vHeXQD"  
[X Link](https://x.com/zohmbastic/status/1999183006146101580)  2025-12-11T18:22Z 10.1K followers, [----] engagements


"$IMMX now well above IPO price $5 $IMMX director Nancy Chang holds 422k shs directly and total about 500k shs. Awarded stock 40k options with [----] exercise price vesting in [--] months Chang was Tanox founder which later acquired by Genetech back in [----] https://www.sec.gov/Archives/edgar/data/1135041/000149315225027329/xslF345X05/ownership.xml $IMMX $3 run ever since daily break https://t.co/sMMLtI9zVh https://www.sec.gov/Archives/edgar/data/1135041/000149315225027329/xslF345X05/ownership.xml $IMMX $3 run ever since daily break https://t.co/sMMLtI9zVh"  
[X Link](https://x.com/zohmbastic/status/1999500138251792610)  2025-12-12T15:22Z 10.1K followers, [----] engagements


"$WEST insiders base formed"  
[X Link](https://x.com/zohmbastic/status/1999516957045842418)  2025-12-12T16:29Z 10.1K followers, [---] engagements


"$OLMA $OLMA Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Olema. The firm says Roche's (RHHBY) positive Phase [--] lidERA trial data shows the "practice changing" $OLMA Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Olema. The firm says Roche's (RHHBY) positive Phase [--] lidERA trial data shows the "practice changing""  
[X Link](https://x.com/zohmbastic/status/2000582240661541041)  2025-12-15T15:02Z 10.1K followers, [----] engagements


"$INAB PIPE priced [----] $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619 IN8bios novel gamma-delta () T cell engager through an Investigational New Drug (IND) application Financing led by Coastlands Capital with participation from new and existing biotechnology investors Initial proceeds extend cash runway into the first half of [----] https://twitter.com/i/web/status/2002001384120426789 https://twitter.com/i/web/status/2002001384120426789"  
[X Link](https://x.com/zohmbastic/status/2002001384120426789)  2025-12-19T13:01Z 10.1K followers, [----] engagements


"$VERA Goldman Sachs [--] from [--] JPMorgan [--] from [--] BofA [--] from [--] Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact assumptions for Vera were revised to reflect a meaningfully larger TAM and higher pricing potential for the APRIL/BAFF inhibitor class in IgAN the analyst tells investors in a research note. https://twitter.com/i/web/status/2002060985763271078 https://twitter.com/i/web/status/2002060985763271078"  
[X Link](https://x.com/zohmbastic/status/2002060985763271078)  2025-12-19T16:58Z 10.1K followers, [----] engagements


"$GAP $GAP nearing [--] $GAP nearing 28"  
[X Link](https://x.com/zohmbastic/status/2002109557137690727)  2025-12-19T20:11Z 10.1K followers, [----] engagements


"$VERA $VERA Goldman Sachs [--] from [--] JPMorgan [--] from [--] BofA [--] from [--] Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact assumptions for $VERA Goldman Sachs [--] from [--] JPMorgan [--] from [--] BofA [--] from [--] Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact assumptions for"  
[X Link](https://x.com/zohmbastic/status/2002118337325904182)  2025-12-19T20:46Z 10.1K followers, [----] engagements


"$AIP daily bnce $AIP Arteris Inc. (Nasdaq: AIP) a leading provider of system IP for accelerating semiconductor creation in the AI era today announced it has entered into a definitive agreement to acquire Cycuity Inc. a leading provider of semiconductor cybersecurity assurance. The addition $AIP Arteris Inc. (Nasdaq: AIP) a leading provider of system IP for accelerating semiconductor creation in the AI era today announced it has entered into a definitive agreement to acquire Cycuity Inc. a leading provider of semiconductor cybersecurity assurance. The addition"  
[X Link](https://x.com/zohmbastic/status/2003164618777330065)  2025-12-22T18:03Z 10.1K followers, [----] engagements


"$TCRX https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/xslF345X03/ownership.xml https://www.sec.gov/Archives/edgar/data/1783328/000090266425005396/xslF345X03/ownership.xml"  
[X Link](https://x.com/zohmbastic/status/2003829765615063098)  2025-12-24T14:07Z 10.1K followers, [----] engagements


"$VERA $VERA Goldman Sachs [--] from [--] JPMorgan [--] from [--] BofA [--] from [--] Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact assumptions for $VERA Goldman Sachs [--] from [--] JPMorgan [--] from [--] BofA [--] from [--] Goldman Sachs raised the firm's price target on Vera Therapeutics to $95 from $55 and keeps a Buy rating on the shares. Following FDA approval and unexpectedly high pricing of Otsuka's Voyxact assumptions for"  
[X Link](https://x.com/zohmbastic/status/2003865115029069929)  2025-12-24T16:27Z 10.1K followers, [----] engagements


"$OMER Jan 10c largest $vol Jan 15c highest OI Jan 20c largest vol $OMER H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant validation" of Omeros value. $OMER H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant"  
[X Link](https://x.com/zohmbastic/status/2003865453836611948)  2025-12-24T16:28Z 10.1K followers, [----] engagements


"$INAB $INAB PIPE priced [----] $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619 IN8bios novel gamma-delta () T cell engager through an Investigational New Drug (IND) application Financing led by Coastlands Capital with participation from $INAB PIPE priced [----] $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619 IN8bios novel gamma-delta () T cell engager through an Investigational New Drug (IND) application Financing led by Coastlands Capital with participation from"  
[X Link](https://x.com/zohmbastic/status/2003879122414788914)  2025-12-24T17:23Z 10.1K followers, [----] engagements


"$OSCR Barclays analyst Andrew Mok upgraded Oscar Health to Equal Weight from Underweight with a price target of $18 up from $13. The firm sees managed care stocks benefiting in [----] from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward "de-rated underperformers." Oscar is priced attractively as the market is currently over-discounting the negative outcomes from expiring subsidies the analyst tells investors in a research note. https://twitter.com/i/web/status/2008170881537671659 https://twitter.com/i/web/status/2008170881537671659"  
[X Link](https://x.com/zohmbastic/status/2008170881537671659)  2026-01-05T13:37Z 10.1K followers, [----] engagements


"$snps $SNPS https://t.co/XKq6AjWHlE $SNPS https://t.co/XKq6AjWHlE"  
[X Link](https://x.com/zohmbastic/status/2008202224854569449)  2026-01-05T15:41Z 10K followers, [----] engagements


"$OVID Point72 13G 6.7M 5.1% $OVID https://t.co/niZF8wEZT6 $OVID https://t.co/niZF8wEZT6"  
[X Link](https://x.com/zohmbastic/status/2008285904880681255)  2026-01-05T21:14Z 10.1K followers, 11.8K engagements


"$HSAI lidar name in china"  
[X Link](https://x.com/zohmbastic/status/2008555629234073786)  2026-01-06T15:05Z 10.1K followers, [----] engagements


"$HSAI near [--] $HSAI lidar name in china https://t.co/N0q96XW6s2 $HSAI lidar name in china https://t.co/N0q96XW6s2"  
[X Link](https://x.com/zohmbastic/status/2008588056333611019)  2026-01-06T17:14Z 10.1K followers, [----] engagements


"$UA $UAA $UA 13D 41.9M 22.2% https://t.co/Is3bekp7Nr $UA 13D 41.9M 22.2% https://t.co/Is3bekp7Nr"  
[X Link](https://x.com/zohmbastic/status/2008624049685971344)  2026-01-06T19:37Z 10K followers, [----] engagements


"$BIOA $BIOA https://t.co/193uoRJuK9 $BIOA https://t.co/193uoRJuK9"  
[X Link](https://x.com/zohmbastic/status/2008641259733426276)  2026-01-06T20:46Z 10K followers, [----] engagements


"$BIOA [--] holla $BIOA 16s in ah $BIOA 16s in ah"  
[X Link](https://x.com/zohmbastic/status/2008654426207351069)  2026-01-06T21:38Z 10K followers, [----] engagements


"$BIOA fyi BIOA ipo was at $18 $BIOA [--] holla $BIOA [--] holla"  
[X Link](https://x.com/zohmbastic/status/2008659587180986878)  2026-01-06T21:58Z 10K followers, [----] engagements


"$OLMA Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market. $OLMA Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from $21 and keeps a Buy rating on the shares. Citi also added an "upside 90-day catalyst watch" on Olema. The firm says Roche's (RHHBY) positive Phase [--] lidERA trial data shows the "practice changing" $OLMA Citi raised the firm's price target on Olema Oncology (OLMA) to $60 from"  
[X Link](https://x.com/zohmbastic/status/2008890117197566153)  2026-01-07T13:15Z 10.1K followers, [----] engagements


"$VTYX overnight session hit 19s VTYX UBS initiated coverage of Ventyx Biosciences with a Buy rating and $20 price target as the analyst initiated or assumed coverage on [--] small-to-mid cap biotech names. After a rough period biotech fundamentals are now inflecting contends the analyst who expects investor confidence to recover and sees this positioning biotech for strong performance in [----]. Among the group top picks include Apogee Therapeutics (APGE) Cogent Biosciences (COGT) Kodiak Sciences (KOD) Ideaya Biosciences (IDYA) Inventiva (IVA) SAB Biotherapeutics (SABS) and Ventyx Biosciences"  
[X Link](https://x.com/zohmbastic/status/2008892711995093200)  2026-01-07T13:25Z 10.1K followers, [----] engagements


"$HSAI pcr .223 for now $HSAI near [--] $HSAI near 27"  
[X Link](https://x.com/zohmbastic/status/2008967190515789853)  2026-01-07T18:21Z 10.1K followers, [----] engagements


"$OLMA daily curl $OLMA Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market. $OLMA Piper Sandler initiated coverage of Olema Oncology with an Overweight rating and $40 price target. The firm believes the company's palazestrant can become the next "backbone" endocrine therapy in the large ER+/HER2- breast cancer market"  
[X Link](https://x.com/zohmbastic/status/2009003718717657343)  2026-01-07T20:46Z 10.1K followers, [----] engagements


"$COST COSTCO WHOLESALE CORPORATION REPORTS DECEMBER SALES RESULTS COSTCO WHOLESALE CORP - REPORTS DECEMBER NET SALES OF $29.86 BLN COSTCO WHOLESALE CORP - DECEMBER COMPARABLE SALES U.S. 6.0% CANADA 8.4% OTHER INTERNATIONAL 10.6%"  
[X Link](https://x.com/zohmbastic/status/2009011607163326960)  2026-01-07T21:17Z 10.1K followers, [----] engagements


"$SKYX NVIDIA Connect Supports Advanced Technology Companies Developing AI-powered Products Part of NVIDIAs Connect Program is to Promote Assist and Identify Go-To-Market Opportunities SKYX Expects to Include its All-In-One Smart Platform and Hub in Collaboration with NVIDIAs AI Features in Future U.S. and Global Projects Including the Upcoming $4 Billion Miami Florida Smart City NVIDIA Connect is Designed to Help Build AI Solutions Faster Accelerate Growth and Maximize Opportunities while Delivering a Range of Significant AI Ecosystem Advantages as Well as Free Benefits SKYXs Technologies"  
[X Link](https://x.com/zohmbastic/status/2009251978992300307)  2026-01-08T13:12Z 10.1K followers, [----] engagements


"$HSAI decent intra flow $HSAI pcr .223 for now https://t.co/6OOp598kVR $HSAI pcr .223 for now https://t.co/6OOp598kVR"  
[X Link](https://x.com/zohmbastic/status/2009284612371960064)  2026-01-08T15:22Z 10.1K followers, [----] engagements


"$GAP $GAP https://t.co/1yz1xvaMLs $GAP https://t.co/1yz1xvaMLs"  
[X Link](https://x.com/zohmbastic/status/2009299896621207745)  2026-01-08T16:23Z 10.1K followers, [----] engagements


"$CZR $CZR some Jan spread trades pcr .168 https://t.co/zTtZ9rkNf6 $CZR some Jan spread trades pcr .168 https://t.co/zTtZ9rkNf6"  
[X Link](https://x.com/zohmbastic/status/2009320676151435326)  2026-01-08T17:45Z 10.1K followers, [----] engagements


"great gap ups on nuclear name $OKLO Oklo And Meta Announce Agreement To Support Development Of A [---] GW Advanced Nuclear Power Campus In Southern Ohio For Meta Data Centers $VST $VSTL $SMR $NNE $IMSR $NKLR reactor names gapping up - $OKLO $SMR $NNE $NKLR $IMSR reactor names gapping up - $OKLO $SMR $NNE $NKLR $IMSR"  
[X Link](https://x.com/zohmbastic/status/2009623190583005235)  2026-01-09T13:48Z 10.1K followers, [----] engagements


"$OLMA back to [--] $OLMA daily curl https://t.co/kWflBZEFDq $OLMA daily curl https://t.co/kWflBZEFDq"  
[X Link](https://x.com/zohmbastic/status/2009728586308067469)  2026-01-09T20:46Z 10.1K followers, [----] engagements


"$BIOA $BIOA fyi BIOA ipo was at $18 $BIOA fyi BIOA ipo was at $18"  
[X Link](https://x.com/zohmbastic/status/2010722963772121307)  2026-01-12T14:38Z 10K followers, [----] engagements


"$SNPS so far so good $SNPS $NVDA NVIDIA and Synopsys Announce Strategic Partnership to Revolutionize Engineering and Design $SNPS $NVDA NVIDIA and Synopsys Announce Strategic Partnership to Revolutionize Engineering and Design"  
[X Link](https://x.com/zohmbastic/status/2010750572178137180)  2026-01-12T16:27Z 10.1K followers, [----] engagements


"$OLMA $OLMA back to [--] https://t.co/0Tg4BbV1Rp $OLMA back to [--] https://t.co/0Tg4BbV1Rp"  
[X Link](https://x.com/zohmbastic/status/2010758965739884921)  2026-01-12T17:01Z 10.1K followers, [----] engagements


"$BILI had 31c on china strength decent so far $BILI https://t.co/CqBLhBM02r $BILI https://t.co/CqBLhBM02r"  
[X Link](https://x.com/zohmbastic/status/2010799384028692982)  2026-01-12T19:41Z 10.1K followers, [----] engagements


"$FRMI Feb 10c 20c spread"  
[X Link](https://x.com/zohmbastic/status/2010810190686310409)  2026-01-12T20:24Z 10.1K followers, [----] engagements


"$RVMD After Revolution Medicines (RVMD) presented pipeline updates and its [----] outlook at a competitor conference in the wake of a report that Merck (MRK) is in talks to acquire Revolution for $28B-$32B Stifel analyst Laura Prendergast said the updates "have us thinking that this speculated $28-32B range might not be enough." As a company policy Revolution does not comment on rumors or speculation notes the analyst whose target price and Buy rating are currently under review as the firm further evaluates the impact of this Revolution M&A speculation and today's updates. $RVMD"  
[X Link](https://x.com/zohmbastic/status/2010811121544872106)  2026-01-12T20:28Z 10K followers, [----] engagements


"$WRBY $WRBY https://t.co/7NaJL72NaJ $WRBY https://t.co/7NaJL72NaJ"  
[X Link](https://x.com/zohmbastic/status/2011087563834945731)  2026-01-13T14:46Z 10.1K followers, [----] engagements


"$WRBY $WRBY https://t.co/0Y7ppI30cj $WRBY https://t.co/0Y7ppI30cj"  
[X Link](https://x.com/zohmbastic/status/2011091155245535444)  2026-01-13T15:01Z 10.1K followers, [----] engagements


"$WRBY 30-31 should be key zone $WRBY https://t.co/oe9cP6M51b $WRBY https://t.co/oe9cP6M51b"  
[X Link](https://x.com/zohmbastic/status/2011092908414308626)  2026-01-13T15:08Z 10.1K followers, [----] engagements


"$BIOA not bad $BIOA https://t.co/iRTunKUKEZ $BIOA https://t.co/iRTunKUKEZ"  
[X Link](https://x.com/zohmbastic/status/2011147833412583571)  2026-01-13T18:46Z 10K followers, [----] engagements


"$ANNX $ANNX daily decent come back https://t.co/ktqSDlKSdc $ANNX daily decent come back https://t.co/ktqSDlKSdc"  
[X Link](https://x.com/zohmbastic/status/2011150521164579232)  2026-01-13T18:57Z 10.1K followers, [----] engagements


"$IMRX insider https://www.sec.gov/Archives/edgar/data/1790340/000179034026000008/xslF345X05/wk-form4_1768396231.xml https://www.sec.gov/Archives/edgar/data/1790340/000179034026000008/xslF345X05/wk-form4_1768396231.xml"  
[X Link](https://x.com/zohmbastic/status/2011432262420844933)  2026-01-14T13:36Z 10.1K followers, [----] engagements


"$WRBY $WRBY 30-31 should be key zone $WRBY 30-31 should be key zone"  
[X Link](https://x.com/zohmbastic/status/2011456523156017180)  2026-01-14T15:13Z 10.1K followers, [----] engagements


"$UNCY $UNCY https://t.co/P4nRI6pCQH $UNCY https://t.co/P4nRI6pCQH"  
[X Link](https://x.com/zohmbastic/status/2011460014905684170)  2026-01-14T15:26Z 10.1K followers, [----] engagements


"$UNCY intra high $UNCY https://t.co/XvKp8MRUJe $UNCY https://t.co/XvKp8MRUJe"  
[X Link](https://x.com/zohmbastic/status/2011498472868921374)  2026-01-14T17:59Z 10.1K followers, [----] engagements


"$TERN daily $TERN daily bnce https://t.co/ahF1ooTg2B $TERN daily bnce https://t.co/ahF1ooTg2B"  
[X Link](https://x.com/zohmbastic/status/2011499177939738763)  2026-01-14T18:02Z 10.1K followers, [----] engagements


"$UAA $UA $UA $UAA another good day https://t.co/8vzkSVkiMd $UA $UAA another good day https://t.co/8vzkSVkiMd"  
[X Link](https://x.com/zohmbastic/status/2011519289753551234)  2026-01-14T19:22Z 10.1K followers, [----] engagements


"$ALHC [--] holla $ALHC UBS raised the firm's price target on Alignment Healthcare to $21 from $18 and keeps a Neutral rating on the shares. $ALHC UBS raised the firm's price target on Alignment Healthcare to $21 from $18 and keeps a Neutral rating on the shares"  
[X Link](https://x.com/zohmbastic/status/2011523140741120495)  2026-01-14T19:37Z 10.1K followers, [----] engagements


"$ANNX $ANNX https://t.co/5nv1prcSGP $ANNX https://t.co/5nv1prcSGP"  
[X Link](https://x.com/zohmbastic/status/2011533568087060659)  2026-01-14T20:19Z 10.1K followers, [----] engagements


"$ZETA Morgan Stanley raised the firm's price target on Zeta Global to $27 from $23. Application SaaS names underperformed both the broader software group and the technology sector in [----] but evidence is building that AI-related risks may prove less severe than initially feared supporting a more constructive outlook for application SaaS in [----] the analyst tells investors in a look-ahead note for the group. However a continued lack of broad-based positive spending revisions keeps the firm "selectively opportunistic" the analyst added. $ZETA https://t.co/tPjd2WQ814 $ZETA https://t.co/tPjd2WQ814"  
[X Link](https://x.com/zohmbastic/status/2011780549761802480)  2026-01-15T12:40Z 10.1K followers, 11K engagements


"$HSAI nice break $HSAI lidar name in china https://t.co/N0q96XW6s2 $HSAI lidar name in china https://t.co/N0q96XW6s2"  
[X Link](https://x.com/zohmbastic/status/2011846966549102851)  2026-01-15T17:04Z 10.1K followers, [----] engagements


"$BILI pcr .103 today $BILI https://t.co/bdd3nA0dP2 $BILI https://t.co/bdd3nA0dP2"  
[X Link](https://x.com/zohmbastic/status/2011866875127361826)  2026-01-15T18:23Z 10K followers, [----] engagements


"$BIOA stopped remaining $bioa [--] $bioa 24"  
[X Link](https://x.com/zohmbastic/status/2011893400384241702)  2026-01-15T20:09Z 10.1K followers, [----] engagements


"$OLMA strong eod $OLMA https://t.co/WgGR9ABDbO $OLMA https://t.co/WgGR9ABDbO"  
[X Link](https://x.com/zohmbastic/status/2011906104565911862)  2026-01-15T20:59Z 10.1K followers, [----] engagements


"$VERO crazy gap up why didn't i take cause it is former $HAIR 😅"  
[X Link](https://x.com/zohmbastic/status/2012147214328660404)  2026-01-16T12:57Z 10.1K followers, [----] engagements


"$ONDS Ondas expects to report revenue of $27.0 to $29.0 million for the quarter ended December [--] [----] 51% higher than the prior Q4 [----] revenue target. For the full year ended December [--] [----] expected revenue is between $47.6 and $49.6 million 23% higher than the prior full-year revenue target for [----]. Ondas' prior revenue targets for Q4 [----] and full-year [----] included a contribution of $3 - [--] million for Roboteam which closed in December [----]. Additionally on a preliminary basis Ondas' estimated backlog is $65.3 million as of December [--] [----] a 180% increase from $23.3 million on"  
[X Link](https://x.com/zohmbastic/status/2012150370693235054)  2026-01-16T13:10Z 10K followers, 16.8K engagements


"$LDI $LDI https://t.co/9wou3PPlYB $LDI https://t.co/9wou3PPlYB"  
[X Link](https://x.com/zohmbastic/status/2012177114569527427)  2026-01-16T14:56Z 10.1K followers, [----] engagements


"$BTDR $BTDR https://t.co/Zs5jeU5bWL $BTDR https://t.co/Zs5jeU5bWL"  
[X Link](https://x.com/zohmbastic/status/2012201838318100844)  2026-01-16T16:34Z 10.1K followers, [----] engagements


"$gmab Truist notes Genmab reported Phase [--] results from the EPCORE DLBCL-1 trial in transplant-ineligible second-line positive diffuse large B-cell lymphoma patients. The study missed its overall survival endpoint. However this outcome does not change the firm's view on the key frontline DLBCL study and Truist remains optimistic for a positive read-out this year. The firm has a Buy rating on the shares with a price target of $48. https://twitter.com/i/web/status/2012256815468191949 https://twitter.com/i/web/status/2012256815468191949"  
[X Link](https://x.com/zohmbastic/status/2012256815468191949)  2026-01-16T20:13Z 10.1K followers, [----] engagements


"$RIOT PTs Piper Sandler [--] Cantor [--] BTIG [--] Clear Street [--] Roth [--] Piper Sandler analyst Patrick Moley reiterated an Overweight rating and $26 price target on Riot Platforms (RIOT) after the company signed a land acquisition and data center lease with AMD (AMD) to host [--] megawatts of critical IT at Rockdale. While the initial deployment is for just [--] MW the firm thinks the deal establishes Riot as a credible data center option for hyperscaler tenants. Piper also views it as an encouraging first step towards Riot eventually contracting all roughly [---] gigawatts of critical IT across"  
[X Link](https://x.com/zohmbastic/status/2012258717908013434)  2026-01-16T20:20Z 10.1K followers, [----] engagements


"$AG nonstop (Periodic table silver symbol) $AU is gold"  
[X Link](https://x.com/zohmbastic/status/2012259330695831918)  2026-01-16T20:23Z 10K followers, [----] engagements


"$INTR Inter (NASDAQ: INTR) the financial institution serving more than [--] million customers has received regulatory approval from the Florida Office of Financial Regulation (OFR) and the Federal Reserve (FED) to establish a statelicensed international banking branch in Florida marking a significant milestone in its international expansion. https://twitter.com/i/web/status/2012266861895790763 https://twitter.com/i/web/status/2012266861895790763"  
[X Link](https://x.com/zohmbastic/status/2012266861895790763)  2026-01-16T20:53Z 10.1K followers, [---] engagements


"$IPSC Venrock https://www.sec.gov/Archives/edgar/data/1738048/000173804826000002/xslSCHEDULE_13G_X01/primary_doc.xml $IPSC Commodore 13M 7.1% https://t.co/6UdSii2vdU https://www.sec.gov/Archives/edgar/data/1738048/000173804826000002/xslSCHEDULE_13G_X01/primary_doc.xml $IPSC Commodore 13M 7.1% https://t.co/6UdSii2vdU"  
[X Link](https://x.com/zohmbastic/status/2012277137911185426)  2026-01-16T21:33Z 10.1K followers, [----] engagements


"$IPSC Ra many bio funds reporting https://www.sec.gov/Archives/edgar/data/1346824/000134682426000006/xslSCHEDULE_13G_X01/primary_doc.xml $IPSC Venrock https://t.co/cPld1D0dao https://www.sec.gov/Archives/edgar/data/1346824/000134682426000006/xslSCHEDULE_13G_X01/primary_doc.xml $IPSC Venrock https://t.co/cPld1D0dao"  
[X Link](https://x.com/zohmbastic/status/2012278036184326349)  2026-01-16T21:37Z 10.1K followers, [----] engagements


"$IMRX $IMRX insider https://t.co/RmBx5DcCel $IMRX insider https://t.co/RmBx5DcCel"  
[X Link](https://x.com/zohmbastic/status/2013635323788411306)  2026-01-20T15:30Z 10.1K followers, [----] engagements


"$UNCY $UNCY intra high $UNCY intra high"  
[X Link](https://x.com/zohmbastic/status/2013636841044353418)  2026-01-20T15:36Z 10.1K followers, [----] engagements


"$TYRA decent loaders"  
[X Link](https://x.com/zohmbastic/status/2013674451829682665)  2026-01-20T18:06Z 10.1K followers, [----] engagements


"$DAWN nice break $DAWN https://t.co/zJru933otu $DAWN https://t.co/zJru933otu"  
[X Link](https://x.com/zohmbastic/status/2013706339667558702)  2026-01-20T20:12Z 10.1K followers, [----] engagements


"$ALMS [--] got avged up with call exercise $ALMS [--] above key https://t.co/k3HaxSS8L0 $ALMS [--] above key https://t.co/k3HaxSS8L0"  
[X Link](https://x.com/zohmbastic/status/2013714116217655661)  2026-01-20T20:43Z 10K followers, [----] engagements


"$ERAS another one that should get good pricing. still holding with call exercise Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers today announced that it intends to offer and sell subject to market and other conditions $150.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Erasca. In addition Erasca intends to grant the"  
[X Link](https://x.com/zohmbastic/status/2013723047040106644)  2026-01-20T21:19Z 10.1K followers, [----] engagements


"$AVR $MDT Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic"  
[X Link](https://x.com/zohmbastic/status/2013734438459322477)  2026-01-20T22:04Z 10.1K followers, [----] engagements


"$AVR decent into close $AVR $MDT Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic $AVR $MDT Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic"  
[X Link](https://x.com/zohmbastic/status/2013777361850802533)  2026-01-21T00:55Z 10K followers, [----] engagements


"$DAWN $DAWN 13s hit in AH $DAWN 13s hit in AH"  
[X Link](https://x.com/zohmbastic/status/2013985937059926512)  2026-01-21T14:44Z 10.1K followers, [----] engagements


"$METC nearing [--] $METC nice block today https://t.co/8YpOJIEyy2 $METC nice block today https://t.co/8YpOJIEyy2"  
[X Link](https://x.com/zohmbastic/status/2013991434005749823)  2026-01-21T15:05Z 10.1K followers, [----] engagements


"$AMKR nice bnce $AMKR https://t.co/srdHgqwaD1 $AMKR https://t.co/srdHgqwaD1"  
[X Link](https://x.com/zohmbastic/status/2013992187730477136)  2026-01-21T15:08Z 10.1K followers, [----] engagements


"$UA $UA $UAA decent intra vol https://t.co/yaW508238d $UA $UAA decent intra vol https://t.co/yaW508238d"  
[X Link](https://x.com/zohmbastic/status/2014005958322561274)  2026-01-21T16:03Z 10.1K followers, [----] engagements


"$UAL UNITED CEO - WE MADE A $500 MILLION PROFIT IN CHICAGO BUT OUR COMPETITOR LOST $500 MILLION"  
[X Link](https://x.com/zohmbastic/status/2014013262669504801)  2026-01-21T16:32Z 10.1K followers, [---] engagements


"$AVO 13s tdoay $AVO https://t.co/HjuThzBiaM $AVO https://t.co/HjuThzBiaM"  
[X Link](https://x.com/zohmbastic/status/2014014292819927197)  2026-01-21T16:36Z 10.1K followers, [----] engagements


"$UA had 2M block today $UA https://t.co/jREeqxoHLA $UA https://t.co/jREeqxoHLA"  
[X Link](https://x.com/zohmbastic/status/2014034894867841115)  2026-01-21T17:58Z 10.1K followers, [----] engagements


"$ALMS $ALMS Charden initiate coverage with a Buy rating PT of $37 based on the potential of its late-stage clinical pipeline in TYK2-mediated autoimmune disorders. Alumis lead asset envudeucitinib is an oral second-gen allosteric TYK2 inhibitor that recently achieved all primary $ALMS Charden initiate coverage with a Buy rating PT of $37 based on the potential of its late-stage clinical pipeline in TYK2-mediated autoimmune disorders. Alumis lead asset envudeucitinib is an oral second-gen allosteric TYK2 inhibitor that recently achieved all primary"  
[X Link](https://x.com/zohmbastic/status/2014049508057829507)  2026-01-21T18:56Z 10.1K followers, [----] engagements


"$UA wen [--] break $UA had 2M block today $UA had 2M block today"  
[X Link](https://x.com/zohmbastic/status/2014051799913689275)  2026-01-21T19:05Z 10.1K followers, [----] engagements


"$ALHC $ALHC [--] holla https://t.co/sboNiN9EOK $ALHC [--] holla https://t.co/sboNiN9EOK"  
[X Link](https://x.com/zohmbastic/status/2014059874250793280)  2026-01-21T19:37Z 10.1K followers, [----] engagements


"$ERAS back above [--] $ERAS another one that should get good pricing. still holding with call exercise Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RAS/MAPK https://t.co/MKi91T85TN $ERAS another one that should get good pricing. still holding with call exercise Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RAS/MAPK https://t.co/MKi91T85TN"  
[X Link](https://x.com/zohmbastic/status/2014072760675315934)  2026-01-21T20:29Z 10.1K followers, [----] engagements


"$IMNM $IMNM https://t.co/urchI8U924 $IMNM https://t.co/urchI8U924"  
[X Link](https://x.com/zohmbastic/status/2014076679153451203)  2026-01-21T20:44Z 10.1K followers, [----] engagements


"$VG On January [--] [----] the International Chamber of Commerce (ICC) International Court of Arbitration informed Venture Global Calcasieu Pass LLC (VGCP) an indirect subsidiary of Venture Global Inc. (Venture Global or the Company) that a final award had been issued in the previously disclosed arbitration proceedings with Repsol LNG Holding S.A. (Repsol) regarding LNG sales from the Calcasieu Project under the long-term LNG sales and purchase agreement entered into by VGCP and Repsol (the SPA). The award issued by the arbitration tribunal found that VGCP had acted as a Reasonable and Prudent"  
[X Link](https://x.com/zohmbastic/status/2014117314866643280)  2026-01-21T23:26Z 10.1K followers, [----] engagements


"$UA https://www.sec.gov/Archives/edgar/data/915191/000094787126000063/xslF345X05/ownership.xml $UA had 2M block today https://www.sec.gov/Archives/edgar/data/915191/000094787126000063/xslF345X05/ownership.xml $UA had 2M block today"  
[X Link](https://x.com/zohmbastic/status/2014143157739409721)  2026-01-22T01:08Z 10.1K followers, [----] engagements


"$ERAS nice pricing Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers today announced the pricing of an upsized public offering of [--------] shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca . The gross proceeds to Erasca from the offering before deducting the underwriting discounts and"  
[X Link](https://x.com/zohmbastic/status/2014328606277685365)  2026-01-22T13:25Z 10.1K followers, [----] engagements


"$KVUE inverse pseudo scientist RFK $KVUE trimmed a few https://t.co/F4CLTqOCTI $KVUE trimmed a few https://t.co/F4CLTqOCTI"  
[X Link](https://x.com/zohmbastic/status/2014360979228741770)  2026-01-22T15:34Z 10K followers, [----] engagements


"$GUTS $GUTS eod vol $GUTS eod vol"  
[X Link](https://x.com/zohmbastic/status/2014366768601399468)  2026-01-22T15:57Z 10K followers, [----] engagements


"$UNCY breaking $UNCY https://t.co/piSmt4aky2 $UNCY https://t.co/piSmt4aky2"  
[X Link](https://x.com/zohmbastic/status/2014367294349050073)  2026-01-22T15:59Z 10.1K followers, [----] engagements


"$RUN bnce continuation"  
[X Link](https://x.com/zohmbastic/status/2014372231145525306)  2026-01-22T16:18Z 10K followers, [----] engagements


"$METC [--] today $METC nearing [--] https://t.co/1Gryq0AXVM $METC nearing [--] https://t.co/1Gryq0AXVM"  
[X Link](https://x.com/zohmbastic/status/2014377374071058929)  2026-01-22T16:39Z 10.1K followers, [----] engagements


"$DAWN intact $DAWN https://t.co/QeRukg5k8I $DAWN https://t.co/QeRukg5k8I"  
[X Link](https://x.com/zohmbastic/status/2014413832374853653)  2026-01-22T19:04Z 10.1K followers, [----] engagements


"$FROG Feb 60c sweep"  
[X Link](https://x.com/zohmbastic/status/2014419773128376364)  2026-01-22T19:27Z 10.1K followers, [----] engagements


"$GTLB seems overdone bnce play took a few"  
[X Link](https://x.com/zohmbastic/status/2014425362743136660)  2026-01-22T19:50Z 10.1K followers, [----] engagements


"$GTLB $GTLB seems overdone bnce play took a few $GTLB seems overdone bnce play took a few"  
[X Link](https://x.com/zohmbastic/status/2014425848565186711)  2026-01-22T19:52Z 10.1K followers, [----] engagements


"$AVR $AVR $MDT Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic $AVR $MDT Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic"  
[X Link](https://x.com/zohmbastic/status/2014432219624878372)  2026-01-22T20:17Z 10.1K followers, [----] engagements


"$VG $VG https://t.co/MG4SgGFiuh $VG https://t.co/MG4SgGFiuh"  
[X Link](https://x.com/zohmbastic/status/2014442153087295863)  2026-01-22T20:56Z 10.1K followers, [----] engagements


"$AVR closed offering [----] $AVR https://t.co/59WAmAZeVD $AVR https://t.co/59WAmAZeVD"  
[X Link](https://x.com/zohmbastic/status/2014443520560357403)  2026-01-22T21:02Z 10.1K followers, [----] engagements


"$FCX UBS analyst Daniel Major raised the firm's price target on Freeport-McMoRan to $70 from $60 and keeps a Buy rating on the shares. $FCX https://t.co/62aqdhLmAp $FCX https://t.co/62aqdhLmAp"  
[X Link](https://x.com/zohmbastic/status/2014684061973811671)  2026-01-23T12:58Z 10.1K followers, [----] engagements


"$BBAR daily $BBAR break https://t.co/2KZLqt8tZ0 $BBAR break https://t.co/2KZLqt8tZ0"  
[X Link](https://x.com/zohmbastic/status/2014730811694628891)  2026-01-23T16:03Z 10.1K followers, [----] engagements


"$QCLS will need to overcome this not soon imo this is $TNFA bio turned into quantum photonics"  
[X Link](https://x.com/zohmbastic/status/2014734865464230136)  2026-01-23T16:19Z 10K followers, [----] engagements


"$FROG $FROG Feb 60c sweep $FROG Feb 60c sweep"  
[X Link](https://x.com/zohmbastic/status/2014735098994725314)  2026-01-23T16:20Z 10.1K followers, [----] engagements


"$METC $METC [--] today https://t.co/hsmmH4eouH $METC [--] today https://t.co/hsmmH4eouH"  
[X Link](https://x.com/zohmbastic/status/2014762574219264492)  2026-01-23T18:10Z 10.1K followers, [----] engagements


"$LDI intraday block today $LDI https://t.co/OEJ3mOdwrZ $LDI https://t.co/OEJ3mOdwrZ"  
[X Link](https://x.com/zohmbastic/status/2014783558368297348)  2026-01-23T19:33Z 10.1K followers, [----] engagements


"$IMNM $IMNM https://t.co/834d06dNBs $IMNM https://t.co/834d06dNBs"  
[X Link](https://x.com/zohmbastic/status/2014784449917886846)  2026-01-23T19:37Z 10.1K followers, [----] engagements


"$METC [--] holla $METC March 35c sweep $METC March 35c sweep"  
[X Link](https://x.com/zohmbastic/status/2014784641408942589)  2026-01-23T19:37Z 10.1K followers, [----] engagements


"$METC they started to notice $METC [--] holla $METC [--] holla"  
[X Link](https://x.com/zohmbastic/status/2014785645370077413)  2026-01-23T19:41Z 10.1K followers, [----] engagements


"$GUTS decent eod $GUTS https://t.co/1HjJqgVn9J $GUTS https://t.co/1HjJqgVn9J"  
[X Link](https://x.com/zohmbastic/status/2014800768755286110)  2026-01-23T20:41Z 10K followers, [----] engagements


"$ERAS Erasca Announces Closing of Upsized Public Offering of Common Stock Including Full Exercise of Underwriters Option to Purchase Additional Shares $ERAS nice pricing Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers today announced the pricing of an upsized public offering $ERAS nice pricing Erasca Inc. (Nasdaq: ERAS) a clinical-stage precision oncology company singularly focused on discovering developing and commercializing therapies for"  
[X Link](https://x.com/zohmbastic/status/2014805898175119592)  2026-01-23T21:02Z 10.1K followers, [----] engagements


"$PGEN Point72 18.4M 5.2% https://www.sec.gov/Archives/edgar/data/1356090/000090266426000427/xslSCHEDULE_13G_X01/primary_doc.xml https://www.sec.gov/Archives/edgar/data/1356090/000090266426000427/xslSCHEDULE_13G_X01/primary_doc.xml"  
[X Link](https://x.com/zohmbastic/status/2014807301098508593)  2026-01-23T21:07Z 10.1K followers, [----] engagements


"$IOBT Novo Holdings decreased stake to 2.47M 3.3% from 4.98M 7.3% Piper Sandler downgraded to [---] from 3"  
[X Link](https://x.com/zohmbastic/status/2014854674034131229)  2026-01-24T00:16Z 10.1K followers, [---] engagements


"$MIST Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)"  
[X Link](https://x.com/zohmbastic/status/2015772864759071068)  2026-01-26T13:04Z 10.1K followers, [---] engagements


"$ERAS Morgan Stanley analyst Sean Laaman raised the firm's price target on Erasca to $10 from $4 and keeps an Equal Weight rating on the shares after the company shared an early clinical look at ERAS-0015 and reported two confirmed partial responses and one unconfirmed PR at [--] mg QD. While these data are "promising" and the firm raised its view of the odds of success as a result it acknowledges "it remains early." $ERAS Erasca Announces Closing of Upsized Public Offering of Common Stock Including Full Exercise of Underwriters Option to Purchase Additional Shares $ERAS Erasca Announces Closing"  
[X Link](https://x.com/zohmbastic/status/2015777128000753708)  2026-01-26T13:21Z 10.1K followers, [----] engagements


"$GTLB $GTLB too fast trimming some https://t.co/AbX80oBDl6 $GTLB too fast trimming some https://t.co/AbX80oBDl6"  
[X Link](https://x.com/zohmbastic/status/2015803224935092237)  2026-01-26T15:05Z 10.1K followers, [----] engagements


"$GTLB [--] holla $GTLB https://t.co/fTbkiOBRhB $GTLB https://t.co/fTbkiOBRhB"  
[X Link](https://x.com/zohmbastic/status/2015807002639794626)  2026-01-26T15:20Z 10.1K followers, [----] engagements


"$GTLB $GTLB [--] holla $GTLB [--] holla"  
[X Link](https://x.com/zohmbastic/status/2015810065928691870)  2026-01-26T15:32Z 10.1K followers, [----] engagements


"$BBAR nearing [--] $BBAR daily https://t.co/5HohxaVA1o $BBAR daily https://t.co/5HohxaVA1o"  
[X Link](https://x.com/zohmbastic/status/2015811892858470708)  2026-01-26T15:39Z 10.1K followers, [----] engagements


"$TEVA nice intra block $TEVA Truist raised the firm's price target on Teva to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into [----] the analyst tells investors in a research note. $TEVA Truist raised the firm's price target on Teva to $36 from $32 and keeps a Buy rating on the shares. The affordable medicines theme remains attractive heading into [----] the analyst tells investors in a research note"  
[X Link](https://x.com/zohmbastic/status/2015839434843750852)  2026-01-26T17:29Z 10.1K followers, [----] engagements


"$GDS weekly $GDS intra high https://t.co/c4bqKRo8Cn $GDS intra high https://t.co/c4bqKRo8Cn"  
[X Link](https://x.com/zohmbastic/status/2015843250985111994)  2026-01-26T17:44Z 10.1K followers, [----] engagements


"$TARA lazy river today $TARA On track to report interim results from approximately [--] six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 [----] Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H [----] Dosed first patient $TARA On track to report interim results from approximately [--] six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 [----] Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H [----] Dosed first patient"  
[X Link](https://x.com/zohmbastic/status/2015845626114711919)  2026-01-26T17:53Z 10.1K followers, [----] engagements


"$DTCX former $TZUP notable bnce"  
[X Link](https://x.com/zohmbastic/status/2015873484597998036)  2026-01-26T19:44Z 10.1K followers, [---] engagements


"$LUNR The National Aeronautics and Space Administration has announced its selection of Intuitive Machines as part of [--] global volunteers chosen to track the Artemis II Mission the company announced. "The company will support the mission using its Space Data Network and ground station infrastructure. Intuitive Machines is among volunteers spanning commercial service providers members of academia and individual amateur radio enthusiasts approved by NASA to track the radio waves transmitted by the Orion spacecraft during its 10-day journey to and around the Moon. The mission's first launch"  
[X Link](https://x.com/zohmbastic/status/2015895032369168646)  2026-01-26T21:10Z 10.1K followers, [----] engagements


"$CAPR Tang 3.4M 6.6% https://www.sec.gov/Archives/edgar/data/1133869/000121465926000831/xslSCHEDULE_13G_X01/primary_doc.xml https://www.sec.gov/Archives/edgar/data/1133869/000121465926000831/xslSCHEDULE_13G_X01/primary_doc.xml"  
[X Link](https://x.com/zohmbastic/status/2015896744215625906)  2026-01-26T21:16Z 10.1K followers, [----] engagements


"$UA $UAA $UAA https://t.co/Dt3kiSRSap $UAA https://t.co/Dt3kiSRSap"  
[X Link](https://x.com/zohmbastic/status/2015935860072477060)  2026-01-26T23:52Z 10.1K followers, [----] engagements


"$BIOA Piper Sandler initiated coverage of BioAge Labs with an Overweight rating and $73 price target. The company's BGE-102 is an oral QD CNS-penetrant NLRP3 inhibitor small-molecule with "strong" Phase [--] data in obese patients the analyst tells investors in a research note. Piper views BioAge as a "key name to own." https://twitter.com/i/web/status/2016121706662822106 https://twitter.com/i/web/status/2016121706662822106"  
[X Link](https://x.com/zohmbastic/status/2016121706662822106)  2026-01-27T12:10Z 10.1K followers, [----] engagements


"$DVN Wells Fargo raised the firm's price target on Devon Energy to $43 from $37 and keeps an Overweight rating on the shares. The oil macro remains pressured with downside-skewed fundamentals as rising OPEC supply and strong non-OPEC growth point to a near-term surplus and continued price pressure Wells notes. Amid a softer macro the firm favors low-reinvestment capital-disciplined frameworks with [----] plans broadly stable across the group. $DVN $CTRA US shale producers Devon Energy and Coterra Energy in merger talks sources say $DVN $CTRA US shale producers Devon Energy and Coterra Energy in"  
[X Link](https://x.com/zohmbastic/status/2016126568767070388)  2026-01-27T12:30Z 10.1K followers, [----] engagements


"$RR Richtech Robotics Collaborates with Microsoft to Advance Agentic AI in Real-World Robotics Applications"  
[X Link](https://x.com/zohmbastic/status/2016134190060736921)  2026-01-27T13:00Z 10.1K followers, [----] engagements


"$ERAS Guggenheim [--] from [--] Mizuho [--] Mizuho analyst Joseph Catanzaro assumed coverage of Erasca with an Outperform rating and price target of $16 up from $5. The firm says the company's RAS inhibitor portfolio is well positioned to establish proof-of-concept in [----]. ERAS-0015 has opportunity for a wider therapeutic window and a competitive clinical profile the analyst tells investors in a research note. $ERAS Morgan Stanley analyst Sean Laaman raised the firm's price target on Erasca to $10 from $4 and keeps an Equal Weight rating on the shares after the company shared an early clinical look"  
[X Link](https://x.com/zohmbastic/status/2016145931679199459)  2026-01-27T13:47Z 10.1K followers, [----] engagements


"$OMER Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA (narsoplimab-wuug) to its distributors were completed last week with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA including patients who have recently failed prior off-label C5-inhibitor regimens in both hospital and outpatient settings. YARTEMLEA is the first and only approved therapy for TA-TMA an often-fatal complication of stem cell"  
[X Link](https://x.com/zohmbastic/status/2016149370492649599)  2026-01-27T14:00Z 10K followers, [----] engagements


"$GDS $GDS weekly https://t.co/JMXNwjCstk $GDS weekly https://t.co/JMXNwjCstk"  
[X Link](https://x.com/zohmbastic/status/2016173378491515170)  2026-01-27T15:36Z 10.1K followers, [----] engagements


"$BILI $BILI pcr .103 today $BILI pcr .103 today"  
[X Link](https://x.com/zohmbastic/status/2016174726503162112)  2026-01-27T15:41Z 10.1K followers, [----] engagements


"$RUN weekly $RUN [--] holla https://t.co/BCRUDRjCFJ $RUN [--] holla https://t.co/BCRUDRjCFJ"  
[X Link](https://x.com/zohmbastic/status/2016183636802863174)  2026-01-27T16:16Z 10.1K followers, [----] engagements


"$eras back above [--] $ERAS Guggenheim [--] from [--] Mizuho [--] Mizuho analyst Joseph Catanzaro assumed coverage of Erasca with an Outperform rating and price target of $16 up from $5. The firm says the company's RAS inhibitor portfolio is well positioned to establish proof-of-concept in [----]. ERAS-0015 $ERAS Guggenheim [--] from [--] Mizuho [--] Mizuho analyst Joseph Catanzaro assumed coverage of Erasca with an Outperform rating and price target of $16 up from $5. The firm says the company's RAS inhibitor portfolio is well positioned to establish proof-of-concept in [----]. ERAS-0015"  
[X Link](https://x.com/zohmbastic/status/2016218676119077224)  2026-01-27T18:36Z 10.1K followers, [----] engagements


"$CTMX Marc 7c $vol 3M April 5c highest OI $Ctmx march 7c good size cons $Ctmx march 7c good size cons"  
[X Link](https://x.com/zohmbastic/status/2016232356470829194)  2026-01-27T19:30Z 10.1K followers, 13.6K engagements


"$TARA [--] today $TARA lazy river today https://t.co/2msQoHjktT $TARA lazy river today https://t.co/2msQoHjktT"  
[X Link](https://x.com/zohmbastic/status/2016244336757784779)  2026-01-27T20:18Z 10.1K followers, [----] engagements


"$MU $MUU $MU Mizuho raised the firm's price target on Micron to $480 from $390 and keeps an Outperform rating on the shares. The firm believes pricing tailwinds in the legacy DRAM and NAND markets will drive better sales and margins in [----] for the memory group. Mizuho expects no new NAND $MU Mizuho raised the firm's price target on Micron to $480 from $390 and keeps an Outperform rating on the shares. The firm believes pricing tailwinds in the legacy DRAM and NAND markets will drive better sales and margins in [----] for the memory group. Mizuho expects no new NAND"  
[X Link](https://x.com/zohmbastic/status/2016246729255837801)  2026-01-27T20:27Z 10.1K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing